Next Article in Journal
Peripheral Brain-Derived Neurotrophic Factor and Contactin-1 Levels in Patients with Attention-Deficit/Hyperactivity Disorder
Previous Article in Journal
Transcatheter Aortic Valve Replacement Is Associated with Less Oxidative Stress and Faster Recovery of Antioxidant Capacity than Surgical Aortic Valve Replacement
Review

Towards Circulating-Tumor DNA-Based Precision Medicine

1
Division of Molecular and Cellular Medicine, National Cancer Centre Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2
Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
3
Department of Breast Surgery, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(9), 1365; https://doi.org/10.3390/jcm8091365
Received: 2 July 2019 / Revised: 6 August 2019 / Accepted: 22 August 2019 / Published: 2 September 2019
(This article belongs to the Section Molecular Diagnostics)
In the era of precision medicine, targeted therapies have been implemented for various diseases. Genomic information guides decision-making in cancer treatment. The improvements in next-generation sequencing and polymerase chain reaction have made it possible to access the genetic information using circulating-tumor DNAs (ctDNAs). Molecular characteristics of individual tumors can be obtained by analysis of ctDNAs, thus making them excellent tools to guide decision-making during treatment. In oncology, the use of ctDNAs in clinical practice is now gaining importance. Molecular analysis of ctDNAs has potential for multiple clinical applications, including early diagnosis, prognosis of disease, prognostic and/or predictive biomarkers, and monitoring response to therapy and clonal evolution. In this paper, we highlight the applications of ctDNAs in cancer management, especially in metastatic setting, and summarize recent studies about the use of ctDNAs as predictive biomarkers for the therapeutic adaptation/response in lung cancer, breast cancer, and colorectal cancer. These studies offer the evidence to use ctDNAs as a promising approach to solve unmet clinical needs. View Full-Text
Keywords: biomarker; breast cancer; circulating-tumor DNA; colorectal cancer; lung cancer; precision medicine; targeted therapy biomarker; breast cancer; circulating-tumor DNA; colorectal cancer; lung cancer; precision medicine; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Hironaka-Mitsuhashi, A.; Sanchez Calle, A.; Ochiya, T.; Takayama, S.; Suto, A. Towards Circulating-Tumor DNA-Based Precision Medicine. J. Clin. Med. 2019, 8, 1365. https://doi.org/10.3390/jcm8091365

AMA Style

Hironaka-Mitsuhashi A, Sanchez Calle A, Ochiya T, Takayama S, Suto A. Towards Circulating-Tumor DNA-Based Precision Medicine. Journal of Clinical Medicine. 2019; 8(9):1365. https://doi.org/10.3390/jcm8091365

Chicago/Turabian Style

Hironaka-Mitsuhashi, Ai, Anna Sanchez Calle, Takahiro Ochiya, Shin Takayama, and Akihiko Suto. 2019. "Towards Circulating-Tumor DNA-Based Precision Medicine" Journal of Clinical Medicine 8, no. 9: 1365. https://doi.org/10.3390/jcm8091365

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop